AstraZeneca Starts Artificial Intelligence Collaboration to Accelerate Drug Discovery

AstraZenecaAstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Scientists from the two organisations will work side-by-side to combine AstraZeneca's genomics, chemistry and clinical data with BenevolentAI's target identification platform and biomedical knowledge graph - a network of contextualised scientific data (genes, proteins, diseases and compounds) and the relationship between them.

Machine learning systematically analyses data to find connections between facts, and AI-based reasoning is used to extrapolate previously unknown connections. Together, the companies will interpret the results to understand the underlying mechanisms of these complex diseases and more quickly identify new potential drug targets.

Mene Pangalos, Executive Vice President and President BioPharmaceuticals R&D, said: "The vast amount of data available to research scientists is growing exponentially each year. By combining AstraZeneca's disease area expertise and large, diverse datasets with BenevolentAI’s leading AI and machine learning capabilities, we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets that could treat debilitating diseases."

Joanna Shields, Chief Executive Officer, BenevolentAI, said: "Millions of people today suffer from diseases that have no effective treatment. The future of drug discovery and development lies in bridging the gap between AI, data, and biology. We are thrilled to be joining forces with AstraZeneca to develop new insights and identify promising new treatments for chronic kidney disease and idiopathic pulmonary fibrosis."

CKD and IPF are complex diseases in which the underlying disease biology is poorly understood. This disease complexity requires the interrogation of vast, rich datasets.

BenevolentAI is a global AI leader focused on drug discovery. The company has developed the Benevolent Platform, an AI discovery platform which can be used by scientists to try to discover novel pathways and mechanisms important in the pathophysiology of disease.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Most Popular Now

Sanofi and Google to Develop New Healthc…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of...

A Miniature Robot that could Check Colon…

Engineers have shown it is technically possible to guide a tiny robotic capsule inside the colon to take micro-ultrasound images. Known as a Sonopill, the device could one day replace...

Call for Startup Pitch Day @ Villeroy …

The Startup Pitch Day is a competition to identify innovative Startups with the aim of creating potential cooperation with Villeroy & Boch Innovations GmbH. Therefore 10 startups are invited to...

Oxford Health Uses Oxehealth Technology …

Oxford Health NHS Foundation Trust has introduced a new observation protocol for checking the safety of patients with severe mental health conditions at night, after a formal evaluation of technology...

Wearable Technology to Personalize Lu-17…

Researchers at the University of Washington in Seattle, Washington, are developing a user-friendly (worn at home) vest with technology that collects data to tailor personalized therapy for patients with metastatic...

3D Body Mapping could Identify, Treat Or…

Medical advancements can come at a physical cost. Often following diagnosis and treatment for cancer and other diseases, patients' organs and cells can remain healed but damaged from the medical...

QUIBIM to Develop Platform in Leading Re…

QUIBIM is helping to advance knowledge of the most lethal pediatric tumors through EU-funded project PRIMAGE, which exploits precision information from medical imaging to establish tumor prognosis, and expected treatment...

MEDICA App COMPETITION 2019 Launches

18 - 21 November 2019, Düsseldorf, Germany. Held in Düsseldorf, the world's leading medical trade fair, MEDICA, is also the world’s number 1 when it comes to start-ups in the health...

Siemens Healthineers, the University of …

Siemens Healthineers, University of Missouri System (UM System) and University of Missouri Health Care (MU Health Care) launch "Alliance for Precision Health." The ten-year collaboration will bring the partners' expertise...

Consumers Less Attentive to News Content…

Heart rate variability decreases and changes in sweat are muted when viewing video news content on smaller screens. Both are indications of reduced attentiveness and engagement with content, according to...

Advanced Therapies Feature in New IMI Ca…

Advanced therapies are a major part of new Innovative Medicines Initiative (IMI) Calls for proposals. The two advanced therapies topics aim to accelerate research into advanced therapies for rare diseases...